Home Tools
Log in
Cart

PD-1/PD-L1

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. Immune checkpoint inhibitors are emerging as a front-line treatment for several types of cancer.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T4696 BMS202 hydrochloride (1675203-84-5(free base)) 2089334-95-0 98%
BMS202 hydrochloride (1675203-84-5(free base))
BMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophys...
T78053 PD-L1-IN-2 2894733-91-4 98%
PD-L1-IN-2
PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity. In vivo studies indicate that it suppress...
T78222 (D)-PPA 1 TFA 98%
(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstrating effi...
T78269 RMP1-14 98%
RMP1-14
RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.
T78270 Anti-Mouse PD-L1 Antibody (10F.9G2) 98%
Anti-Mouse PD-L1 Antibody (10F.9G2)
Anti-Mouse PD-L1 Antibody is a rat-derived IgG2b monoclonal antibody that inhibits mouse PD-L1.
T78330 Peresolimab 2411580-63-5 98%
Peresolimab
Peresolimab, a humanized IgG1-κ antibody, targets PD-1 and may activate physiological immune inhibitory pathways, thereby restoring immune homeostasis [1] [2].
T78755 PD-1/PD-L1-IN-31 98%
PD-1/PD-L1-IN-31
PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral blood mononuclea...
T79205 PD-1/PD-L1-IN-34 2924403-17-6 98%
PD-1/PD-L1-IN-34
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1/PD-L1 interaction (IC 50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1 (...
T79314 PD-L1-IN-3 98%
PD-L1-IN-3
PD-L1-IN-3 (Compound 4a) functions as an inhibitor targeting the PD-1/PD-L1 axis, with an IC50 value of 4.97nM for PD-L1 inhibition and an EC50 value of 2.70 μM ...
T79528 SWS1 2922115-32-8 98%
SWS1
SWS1, a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM), displays anticancer activity by augmenting tumor-infiltrating lymphocytes and demonstrating anti-...
T79576 PD-1/PD-L1-IN-32 98%
PD-1/PD-L1-IN-32
PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM. It effectively suppr...
T79643 PD-1/PD-L1-IN-33 2975602-78-7 98%
PD-1/PD-L1-IN-33
PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM. By doing so, it enhan...
T79705 LP23 98%
LP23
LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/Jurkat T...
T80209 Human membrane-bound PD-L1 polypeptide 1831010-13-9 98%
Human membrane-bound PD-L1 polypeptide
Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].
T80569 Benmelstobart 2303884-58-2 98%
Benmelstobart
Benmelstobart, an IgG1κ antibody, targets PD-L1/CD274 and is of murine origin [1].
T80582 Acrixolimab 2506324-29-2 98%
Acrixolimab
Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].
T80611 Sasanlimab 2206792-50-7 98%
Sasanlimab
Sasanlimab (PF-06801591), a humanized IgG4-κ antibody, selectively targets PD-1 and is primarily produced in Chinese Hamster Ovary (CHO) cells [1].
T80617 Reozalimab 2445259-99-2 98%
Reozalimab
Rezilimab is a bispecific antibody that targets PD-1/PD-L1 and mediates antibody-dependent cell cytotoxicity (ADCC) in cancer research [1] [2].
T80619 Rosnilimab 2412764-40-8 98%
Rosnilimab
Rosnilimab is a humanized IgG1-κ antibody that targets PD-1 [1] [2].
T80863 Visugromab 2556646-63-8 98%
Visugromab
Visugromab, a GDF-15 neutralizing IgG4 monoclonal antibody (mAb), demonstrates potent efficacy in treating PD-1/PD-L1 relapsed/refractory metastatic solid tumors...
BMS202 hydrochloride (1675203-84-5(free base))
T4696
BMS202 hydrochloride (1675203-84-5(free base)) (PD-1/PD-L1 inhibitor 2 hydrochloride) is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophys...
PD-L1-IN-2
T78053
PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity. In vivo studies indicate that it suppress...
(D)-PPA 1 TFA
T78222
(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstrating effi...
RMP1-14
T78269
RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.
Anti-Mouse PD-L1 Antibody (10F.9G2)
T78270
Anti-Mouse PD-L1 Antibody is a rat-derived IgG2b monoclonal antibody that inhibits mouse PD-L1.
Peresolimab
T78330
Peresolimab, a humanized IgG1-κ antibody, targets PD-1 and may activate physiological immune inhibitory pathways, thereby restoring immune homeostasis [1] [2].
PD-1/PD-L1-IN-31
T78755
PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral blood mononuclea...
PD-1/PD-L1-IN-34
T79205
PD-1/PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1/PD-L1 interaction (IC 50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1 (...
PD-L1-IN-3
T79314
PD-L1-IN-3 (Compound 4a) functions as an inhibitor targeting the PD-1/PD-L1 axis, with an IC50 value of 4.97nM for PD-L1 inhibition and an EC50 value of 2.70 μM ...
SWS1
T79528
SWS1, a d-(+)-biotin-conjugated PD-L1 inhibitor (IC50: 1.8 nM), displays anticancer activity by augmenting tumor-infiltrating lymphocytes and demonstrating anti-...
PD-1/PD-L1-IN-32
T79576
PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM. It effectively suppr...
PD-1/PD-L1-IN-33
T79643
PD-1/PD-L1-IN-33 (Compound N11), a PD-1/PD-L1 inhibitor, effectively impedes the interaction between PD-1 and PD-L1 with an IC50 of 6.3 nM. By doing so, it enhan...
LP23
T79705
LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/Jurkat T...
Human membrane-bound PD-L1 polypeptide
T80209
Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].
Benmelstobart
T80569
Benmelstobart, an IgG1κ antibody, targets PD-L1/CD274 and is of murine origin [1].
Acrixolimab
T80582
Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].
Sasanlimab
T80611
Sasanlimab (PF-06801591), a humanized IgG4-κ antibody, selectively targets PD-1 and is primarily produced in Chinese Hamster Ovary (CHO) cells [1].
Reozalimab
T80617
Rezilimab is a bispecific antibody that targets PD-1/PD-L1 and mediates antibody-dependent cell cytotoxicity (ADCC) in cancer research [1] [2].
Rosnilimab
T80619
Rosnilimab is a humanized IgG1-κ antibody that targets PD-1 [1] [2].
Visugromab
T80863
Visugromab, a GDF-15 neutralizing IgG4 monoclonal antibody (mAb), demonstrates potent efficacy in treating PD-1/PD-L1 relapsed/refractory metastatic solid tumors...
1 2 3
TargetMol